The Zolgensma cancer risk is now a confirmed regulatory question, not a theoretical one. On 6 November 2026 the US Food and Drug Administration, through its Center for Biologics Evaluation and Research, published a safety communication about postmarketing reports of malignancies in patients treated with Zolgensma, known by its generic name onasemnogene abeparvovec. Zolgensma is a one-time gene therapy for spinal muscular atrophy, a serious condition that weakens muscles in babies and young children. Novartis disclosed on 5 November that it had received nine tumour reports since the therapy's first approval in the United States in May 2019. Three of the nine involved a gene called GLI1, which is an oncogene, a gene that can drive cancer when it is switched on in the wrong way. In two of those three cases, molecular analysis of tumour tissue showed that the therapy's AAV9 vector DNA had integrated into the patient's genome, with the promoter region inserted upstream of or within GLI1. That finding is what makes this case new. The FDA described it as the first confirmed instance of a commercially approved gene therapy's vector causing tumours. More than 6,000 children have received Zolgensma since 2019, so the nine reports are rare against that total, but the confirmed mechanism in two cases changes how the risk must be described, monitored and labelled.

Zolgensma Cancer Risk: What the FDA Announced on 6 November 2026

The FDA safety communication was published on 6 November 2026 by the Center for Biologics Evaluation and Research. It reported postmarketing reports of malignancies in patients treated with Zolgensma. Postmarketing reports are reports that arrive after a medicine has been approved and is in wider use, and they are a normal part of how regulators track safety over time. In this case the reports were tumours. Novartis disclosed on 5 November, one day before the FDA communication, that it had received nine tumour reports since the therapy's first US approval in May 2019. The nine reports cover a period of more than seven years, from May 2019 to November 2026. The tumours involved the central and peripheral nervous systems, the spinal and paraspinal regions, and the kidney. That spread of locations matters because it shows the reports were not confined to one part of the body. The two confirmed cases developed tumours 18 to 60 months after infusion, which means the tumours appeared a year and a half to five years after treatment, not immediately. That long gap is one reason long-term follow-up matters for gene therapies, and it is also why the FDA is looking at long-term follow-up studies as part of its response.

The mechanism in the third GLI1 case remains under investigation. That is an important limit on what is known. Three of the nine reports involved GLI1. In two of those three, molecular analysis of tumour tissue showed the AAV9 vector DNA had integrated into the patient's genome, with the promoter region inserted upstream of or within GLI1. In plain terms, a piece of the delivery vehicle used by the therapy ended up inside the patient's own DNA, next to or inside a gene that can drive cancer, and the promoter region that switches genes on was placed where it could switch that gene on. The FDA called this insertional oncogenesis, meaning cancer caused by an insertion into the genome. The third GLI1 case has not yet been explained in the same way, and the mechanism there remains under investigation. The other six tumour reports are not described in the verified facts as GLI1 cases, and their mechanisms are not stated here. Precision matters in this story. The therapy has not been shown in general to cause cancer. What has been confirmed is insertional oncogenesis in two cases, within a total of nine tumour reports.

Background: What Zolgensma Is and Who Receives It

Zolgensma, or onasemnogene abeparvovec, is a one-time gene therapy for spinal muscular atrophy. Spinal muscular atrophy, often shortened to SMA, is a condition in which a faulty gene leaves the body unable to make enough of a protein that motor neurons need to survive. Motor neurons carry signals from the brain and spinal cord to muscles, so when they are lost, muscles weaken and waste away. In babies, the condition can be severe and life-limiting. Zolgensma works by delivering a working copy of the gene into the body in a single infusion, using a delivery vehicle called an AAV9 vector. AAV stands for adeno-associated virus, a virus that has been adapted for use as a delivery vehicle because it can carry genetic material into cells. The vector is the carrier. The therapy itself is the genetic material it carries, plus the instructions that tell cells to use it. More than 6,000 children have received Zolgensma since 2019, according to the verified figures in this story. That number gives the scale of use against which the nine tumour reports must be read.

The current label still calls the Zolgensma cancer risk theoretical. That wording now sits in tension with the confirmed findings. The label describes a risk that was thought possible in theory but had not been seen in practice. The FDA has now confirmed insertional oncogenesis in two cases, which means the risk is no longer only theoretical in those cases. The FDA said it is expeditiously evaluating the label and long-term follow-up studies. Expeditiously means quickly, and the label is the official document that tells doctors and patients what is known about a medicine, including its risks. Changing a label is a formal process, and the FDA's statement signals that the wording will be reviewed in light of the new evidence. The risk applies to both Zolgensma and Itvisma. Zolgensma is given by intravenous infusion, known as IV, to children under two. Itvisma is given intrathecally, meaning into the fluid around the spinal cord, to patients aged two and older, and it was approved on 24 November 2025. The two products share the same vector and construct, so the risk applies to both. No neoplasia cases have been reported after Itvisma to date. Neoplasia is the medical term for the formation of new, abnormal growths, including tumours.

Zolgensma Cancer Risk: The Nine Reports and the Two Confirmed Cases

The numbers in this story need to be kept in order. Nine tumour reports have been received by Novartis since the first US approval in May 2019. Three of the nine involved the GLI1 oncogene. In two of those three, molecular analysis of tumour tissue showed the AAV9 vector DNA had integrated into the patient's genome, with the promoter region inserted upstream of or within GLI1. The mechanism in the third GLI1 case remains under investigation. The two confirmed cases developed tumours 18 to 60 months after infusion. The tumours involved the central and peripheral nervous systems, the spinal and paraspinal regions, and the kidney. More than 6,000 children have received Zolgensma since 2019. The FDA described this as the first confirmed instance of a commercially approved gene therapy's vector causing tumours. That characterisation is the FDA's, and it is what makes the announcement notable beyond the nine reports themselves. Gene therapies have long carried a theoretical risk of insertional oncogenesis, because any therapy that puts genetic material into cells carries some chance that the material will land in the wrong place. Until now, that risk had not been confirmed for a commercially approved gene therapy. It has now been confirmed in two cases.

The distinction between nine reports and two confirmed cases is the heart of the Zolgensma cancer risk story. Nine is the count of tumour reports received. Two is the count of cases in which the vector's role was confirmed by molecular analysis of tumour tissue. The other reports, including the third GLI1 case, do not carry the same confirmed mechanism in the verified facts. That does not mean they are unimportant. It means the evidence is strongest for the two confirmed cases, and the investigation continues for the rest. The timing also matters. The two confirmed cases developed tumours 18 to 60 months after infusion, a long interval that underlines why follow-up over years, not months, is needed for children who receive a one-time gene therapy. A medicine given once in infancy can have effects that appear years later, and a safety system that stops watching after a year would miss them. The FDA's focus on long-term follow-up studies reflects that point.

Why It Matters: Benefits, Risks and the Label

The FDA said the overall benefits of Zolgensma continue to outweigh the risks for approved uses. That is a clear statement, and it is why there has been no recall, no market withdrawal and no clinical hold. Those three actions would each be a major regulatory step. A recall removes a product from use. A market withdrawal takes it off the market. A clinical hold stops studies. None of those has happened. The FDA's position is that the therapy should continue to be available for the children it is approved for, while the risk is evaluated and the label is updated. That balance, benefit against risk, is the standard framework regulators use. For spinal muscular atrophy, the benefit is treatment for a severe condition in very young children. The risk, as now confirmed in two cases, is a rare but serious one. The FDA's statement that benefits continue to outweigh risks is a judgement about the population of approved patients as a whole, not a guarantee for any single child. Families and doctors must weigh the same facts for each individual case, with the new information in front of them.

The label question is the most concrete next step in the Zolgensma cancer risk story. The current label still calls the risk theoretical. The FDA is expeditiously evaluating the label and long-term follow-up studies. A label that calls a risk theoretical when two cases have been confirmed would be out of date, and the evaluation is meant to bring the wording into line with the evidence. The risk applies to both Zolgensma and Itvisma because they share the same vector and construct, even though no neoplasia cases have been reported after Itvisma to date. Itvisma was approved on 24 November 2025 for patients aged two and older, given intrathecally, while Zolgensma is given by IV to children under two. The shared vector means the same mechanism could in principle occur in either product, which is why the FDA's communication covers both. For readers following other fast-moving health stories, the scale of recent US measles cases is covered in US measles cases at 5,182, the highest since 1991.

Key Facts at a Glance

The FDA safety communication was published on 6 November 2026 by the Center for Biologics Evaluation and Research. Novartis disclosed on 5 November that it had received nine tumour reports since the therapy's first US approval in May 2019. Three of the nine involved the GLI1 oncogene. In two of those three, molecular analysis of tumour tissue showed the AAV9 vector DNA had integrated into the patient's genome, with the promoter region inserted upstream of or within GLI1. The mechanism in the third GLI1 case remains under investigation. The two confirmed cases developed tumours 18 to 60 months after infusion. The tumours involved the central and peripheral nervous systems, the spinal and paraspinal regions, and the kidney. More than 6,000 children have received Zolgensma since 2019. The FDA described this as the first confirmed instance of a commercially approved gene therapy's vector causing tumours. The current label still calls the risk theoretical. The FDA is expeditiously evaluating the label and long-term follow-up studies. The risk applies to both Zolgensma, given by IV to children under two, and Itvisma, given intrathecally to patients aged two and older and approved on 24 November 2025, because they share the same vector and construct. No neoplasia cases have been reported after Itvisma to date. There is no recall, market withdrawal or clinical hold. The FDA said overall benefits continue to outweigh risks for approved uses. Providers have been told to monitor for tumours and to report to Novartis Gene Therapies on 1-833-828-3947 or to FDA MedWatch on 1-800-FDA-1088.

The reporting routes are part of the safety system, not a footnote. Providers who see a tumour in a patient treated with Zolgensma or Itvisma are told to report it, either to Novartis Gene Therapies or to FDA MedWatch. Those reports are how postmarketing safety works: the more complete the reporting, the clearer the picture of how common a risk is and who it affects. The nine reports so far came through that system, and the two confirmed cases were confirmed because tumour tissue was available for molecular analysis. Without tissue analysis, the link between the vector and the tumour could not have been shown. That is a practical point for doctors: when a tumour appears in a treated patient, tissue analysis matters, because it is the evidence that can confirm or rule out insertional oncogenesis. The Canadian flu season arriving early is a separate public-health story covered in Canada's flu season, seven weeks early.

What Happens Next: Monitoring, Labelling and Long-Term Follow-Up

The next steps in the Zolgensma cancer risk investigation are monitoring, labelling and long-term follow-up. Providers have been told to monitor for tumours in patients treated with Zolgensma and Itvisma, and to report cases to Novartis Gene Therapies on 1-833-828-3947 or to FDA MedWatch on 1-800-FDA-1088. Monitoring means watching for signs of tumours over years, not just in the months after infusion, because the two confirmed cases developed tumours 18 to 60 months after infusion. Long-term follow-up studies are part of the FDA's evaluation, and they are the mechanism by which regulators will learn whether more cases appear, how long after treatment they appear, and whether particular groups of patients are at higher risk. The label evaluation is the other immediate step. The current label still calls the risk theoretical, and the FDA is expeditiously evaluating it, which points to updated wording that reflects the confirmed cases.

The wider question is what this means for gene therapy as a field. The FDA's characterisation, that this is the first confirmed instance of a commercially approved gene therapy's vector causing tumours, sets a precedent. It shows that insertional oncogenesis, long discussed as a theoretical risk, can occur in practice with a commercial product. That does not end gene therapy, and the FDA's statement that benefits continue to outweigh risks for approved uses makes that clear. It does mean that future gene therapies will face closer questions about vector design, about where the vector can integrate, and about how long patients must be followed. For families of children with spinal muscular atrophy, the immediate question is practical: what to watch for, and how to report it. The answer in the FDA communication is monitoring for tumours and reporting through the routes given. For the nine reports, the investigation continues, including the third GLI1 case, where the mechanism remains under investigation. The confirmed facts are two cases of insertional oncogenesis, nine reports in total, more than 6,000 children treated since 2019, no recall, no withdrawal, no clinical hold, and a label under expeditious review.

Sources

US FDA; TradingView/DPA; The Hindu BusinessLine. November 2026.